Cardiovascular Systems Stock Forecast, Price & News

Cardiovascular Systems' stock was trading at $36.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CSII stock has increased by 23.0% and is now trading at $44.67.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cardiovascular Systems stock.
View analyst ratings for Cardiovascular Systems or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Cardiovascular Systems a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cardiovascular Systems wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Cardiovascular Systems.

Cardiovascular Systems will be holding an earnings conference call on Wednesday, February 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Cardiovascular Systems, Inc. (NASDAQ:CSII) released its quarterly earnings data on Wednesday, November, 4th. The medical device company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.18. The medical device company had revenue of $60.54 million for the quarter, compared to analyst estimates of $56.27 million. Cardiovascular Systems had a negative return on equity of 11.43% and a negative net margin of 10.12%.
View Cardiovascular Systems' earnings history.

Cardiovascular Systems updated its second quarter 2021 After-Hours earnings guidance on Wednesday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63-67 million, compared to the consensus revenue estimate of $66.01 million.

7 brokerages have issued 12-month target prices for Cardiovascular Systems' stock. Their forecasts range from $45.00 to $50.00. On average, they expect Cardiovascular Systems' share price to reach $47.00 in the next year. This suggests a possible upside of 5.2% from the stock's current price.
View analysts' price targets for Cardiovascular Systems or view Wall Street analyst' top-rated stocks.

Cardiovascular Systems saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 1,400,000 shares, an increase of 41.2% from the December 15th total of 991,400 shares. Based on an average daily trading volume, of 292,300 shares, the short-interest ratio is presently 4.8 days.
View Cardiovascular Systems' Short Interest.

Some companies that are related to Cardiovascular Systems include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Insulet (PODD), Teleflex (TFX) and Varian Medical Systems (VAR).
View all of CSII's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include Gilead Sciences (GILD), AbbVie (ABBV), Advanced Micro Devices (AMD), Medtronic (MDT), Pfizer (PFE), (XEL), ACADIA Pharmaceuticals (ACAD), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and The Procter & Gamble (PG).

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Cardiovascular Systems' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.08%) and Diversified Trust Co (0.04%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb and Sandra Sedo.
View institutional ownership trends for Cardiovascular Systems.

CSII stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, and Sandra Sedo.
View insider buying and selling activity for Cardiovascular Systems or view top insider-selling stocks.

CSII stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have bought Cardiovascular Systems stock in the last two years include Erik Paulsen, Martha Goldberg Aronson, and Rhonda J Robb.
View insider buying and selling activity for Cardiovascular Systems or or view top insider-buying stocks.

Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CSII stock can currently be purchased for approximately $44.67.

Cardiovascular Systems has a market capitalization of $1.79 billion and generates $236.54 million in revenue each year. The medical device company earns $-27,240,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Cardiovascular Systems employs 779 workers across the globe.

The official website for Cardiovascular Systems is www.csi360.com.

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]